Conference Coverage
Conference Coverage
Atezolizumab plus chemotherapy superior to best supportive care in early lung cancer
Interim DFS analysis shows that relapse was higher among patients receiving best supportive care, compared with patients who received atezolizumab...
Conference Coverage
Study supports chemotherapy with immunotherapy for some never-smokers with lung cancer
Although patients with PD-L1 expression below 50% derive clear benefit from combination versus single-agent therapy, treatment selection overall...
Conference Coverage
Updates to CDC’s STI guidelines relevant to midlife women too
An uptick in STIs, especially syphilis, in perimenopausal and postmenopausal women means the new STI recommendations from the CDC are relevant for...
Conference Coverage
First-line bevacizumab-osimertinib disappoint in EGFR-mutant NSCLC
The combination provided no added progression-free survival benefit over osimertinib monotherapy for EGFR-mutated nonsquamous NSCLC, but raised...
Conference Coverage
Combination treatment shows promise for men with advanced prostate cancer
The combination of nivolumab and rucaparib in a clinical trial showed clinical activity for metastatic prostate cancer cases with BRCA mutations....
Conference Coverage
Early vs. late TNFi switch in AS patients associated with different risk factors
Different factors were associated with switching an initial TNF inhibitor within 2 years versus after 2 years of treatment.
Conference Coverage
EASD: Precision in diabetes management and impact of COVID-19
The European Association for the Study of Diabetes annual meeting will feature precision medicine sessions, a consensus statement on type 1...
Conference Coverage
Long COVID appears to ‘impair’ survival in cancer patients
Conference Coverage
Remdesivir sharply cuts COVID hospitalization risk, Gilead says
Conference Coverage
Sexual assault in women tied to increased stroke, dementia risk
“A history of sexual assault was particularly related to white matter hyperintensities in the parietal lobe, [which] have been linked to Alzheimer...
Conference Coverage
Datopotamab deruxtecan for advanced NSCLC encouraging so far
The ongoing TROPION-PanTumor01 clinical trial shows an overall response rate of 35% for patients with advanced or metastatic NSCLC.